Our Capabilities

Driving Better Outcomes in Oncology

Maximizing the commercial impact of oncology therapies, especially for tough-to-treat patient populations, is challenging for many reasons. Patient groups are often small and heterogeneous. There’s often limited clinical data. This creates a paradox where both scientific precision and scalable access strategies must be balanced to address the high unmet need.

The Secura Bio team has decades of experience navigating these complexities to shape the impact of some of oncology’s largest clinical and market opportunities. Our success is built on four habits engrained in our cross-functional, customer-facing teams:

• Understand the challenges of treating oncology patients, particularly in the most difficult-to-treat populations
• Listen to feedback about what’s working and what is not
• Take action to address challenges swiftly and effectively
• Work with our global team to expand the possibilities to help the most patients

On this foundation, Secura Bio has proven our ability to optimize sales for approved indications and pioneer clinical trial protocols in T cell cancers to address significant unmet need.

Our High-Touch Difference

Too often, lack of experience in a sophisticated commercial marketplace, an inability to maximize commercial success with a clinical development plan, and sluggish response times lead to missed opportunities to generate value. We’ve created a high-touch commercialization approach to ensure every value-driving possibility can be unlocked.

• 
  KNOWLEDGE ACQUISITION. We dive swiftly and deeply into new areas of oncology, leveraging our team’s expertise, relationships, and geographical synergies to rapidly commercialize therapies.
• 
  TECHNICAL INFRASTRUCTURE. Our infrastructure is designed to clinically investigate new opportunities and ensure seamless delivery throughout the supply chain as well as the timely flow of information between relevant parties.
• 
  SCALE UP. We rapidly build expert teams to meet the organizational needs of expanding into new indications, including executing the first-ever Phase 3 trial in patients with the T follicular helper (TFH) phenotype of nodal T Cell Lymphoma.

Patient-Centered Clinical Strategy

We leave no stone unturned to find the patients who will benefit most from our therapies. We leverage our biomarker-driven clinical development and regulatory science capabilities to optimize patient stratification and investigate intriguing observations from our field teams and insights from our clinical trials.

We are working diligently to expand our flagship therapy, duvelisib, into peripheral T cell lymphoma (PTCL) based on clinical data, which indicate the drug may have  potential to benefit patients with T-Follicular Helper subtype; an underserved patient group.